Apellis Pharmaceuticals Inc.

10/02/2022 | Press release | Distributed by Public on 10/02/2022 15:53

Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: 24-Month Results from the Phase 3 OAKS and DERBY Trials